To further delineate the role of EGFR and its downstream signaling pathways in JMV/EGF-induced cell proliferation, we treated AML 12 cells with PP2 (Src inhibitor), erlotinib (EGFR inhibitor), cobimetinib (MEK inhibitor), Calphostin C (PKC inhibitor), wortmannin (PI3K inhibitor), or DMSO control 30 minutes prior to the addition of JMV and/or EGF. This evidence concerns the gene SRC and acute myeloid leukemia.